Analyst David Martin PhD of Bloom Burton maintained a Buy rating on Microbix Biosystms (MBX – Research Report), reducing the price target to C$0.80.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
David Martin PhD has given his Buy rating due to a combination of factors, including Microbix Biosystems’ strategic positioning and market dynamics. The company benefits from the exemption of its products from tariffs under the USMCA trade agreement, which supports its sales into the U.S. market. This exemption provides a stable revenue stream from North America, despite challenges in other regions.
Additionally, while there has been a halt in antigen sales to China due to a reduced demand linked to a lighter burden of respiratory diseases, other markets such as North America and Western Europe remain unaffected. This geographical diversification and the continued demand for their QAPs products contribute to a positive outlook for the company, justifying the Buy rating.
MBX’s price has also changed slightly for the past six months – from C$0.345 to C$0.375, which is a 8.70% increase.